LivaNova Comments on the U.S. Centers for Medicare & Medicaid Services’ Reconsideration of its National Coverage Determination for VNS Therapy for Treatment-Resistant Depression

LivaNova issued a statement in regard to the U.S. Centers for Medicare & Medicaid Services’ publication of a tracking sheet to reconsider its National Coverage Determination for the Company’s Vagus Nerve Stimulation Therapy® System for Treatment-Resistant Depression.